Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma

KAZUKI MAESAKA, RYOTARO SAKAMORI, RYOKO YAMADA, YUKI TAHATA, KAZUYOSHI OHKAWA, MASAHIDE OSHITA, SHINJI TAMURA, HIDEKI HAGIWARA, EIJI MITA, TAKAYUKI YAKUSHIJIN, MASAMI INADA, TAKAHIRO KODAMA, HAYATO HIKITA, TOMOHIDE TATSUMI and TETSUO TAKEHARA
Anticancer Research April 2021, 41 (4) 2187-2192; DOI: https://doi.org/10.21873/anticanres.14993
KAZUKI MAESAKA
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOTARO SAKAMORI
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOKO YAMADA
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKI TAHATA
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUYOSHI OHKAWA
2Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAHIDE OSHITA
3Department of Gastroenterology and Hepatology, Osaka Police Hospital, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINJI TAMURA
4Department of Gastroenterology and Hepatology, Minoh City Hospital, Minoh, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEKI HAGIWARA
5Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EIJI MITA
6Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAYUKI YAKUSHIJIN
7Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAMI INADA
8Department of Gastroenterology and Hepatology, Toyonaka Municipal Hospital, Toyonaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAHIRO KODAMA
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HAYATO HIKITA
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOHIDE TATSUMI
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSUO TAKEHARA
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: takehara@gh.med.osaka-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml. Patients and Methods: In our prospectively registered, real-world cohort, 13 and 11 patients treated with ramucirumab or sorafenib, respectively, were analyzed. Progression-free survival (PFS) was primarily compared between the ramucirumab and sorafenib groups. Results: The PFS was significantly longer in the ramucirumab group than in the sorafenib group (median, 2.7 vs. 0.9 months, respectively; p=0.005). There were no significant differences in the objective response rates or the disease control rates between the ramucirumab and sorafenib groups (9.1% and 54.5% vs. 0.0% and 22.2%, respectively). Conclusion: Subsequent systemic therapy with ramucirumab showed a better ability to control tumor progression than sorafenib in HCC patients with serum AFP levels ≥400 ng/ml.

Key Words:
  • Ramucirumab
  • sorafenib
  • hepatocellular carcinoma
  • α-Fetoprotein
  • subsequent systemic therapy
  • Received March 5, 2021.
  • Revision received March 11, 2021.
  • Accepted March 12, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (4)
Anticancer Research
Vol. 41, Issue 4
April 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma
KAZUKI MAESAKA, RYOTARO SAKAMORI, RYOKO YAMADA, YUKI TAHATA, KAZUYOSHI OHKAWA, MASAHIDE OSHITA, SHINJI TAMURA, HIDEKI HAGIWARA, EIJI MITA, TAKAYUKI YAKUSHIJIN, MASAMI INADA, TAKAHIRO KODAMA, HAYATO HIKITA, TOMOHIDE TATSUMI, TETSUO TAKEHARA
Anticancer Research Apr 2021, 41 (4) 2187-2192; DOI: 10.21873/anticanres.14993

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma
KAZUKI MAESAKA, RYOTARO SAKAMORI, RYOKO YAMADA, YUKI TAHATA, KAZUYOSHI OHKAWA, MASAHIDE OSHITA, SHINJI TAMURA, HIDEKI HAGIWARA, EIJI MITA, TAKAYUKI YAKUSHIJIN, MASAMI INADA, TAKAHIRO KODAMA, HAYATO HIKITA, TOMOHIDE TATSUMI, TETSUO TAKEHARA
Anticancer Research Apr 2021, 41 (4) 2187-2192; DOI: 10.21873/anticanres.14993
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Feasibility of Computed Tomography-guided Percutaneous Renal Cryoablation Under Local Anesthesia: A Single Center Experience in Taiwan
  • Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
  • Gastric Linitis Plastica: Clinical Characteristics and Outcomes from the National Cancer Database
Show more Clinical Studies

Similar Articles

Keywords

  • ramucirumab
  • Sorafenib
  • hepatocellular carcinoma
  • α-fetoprotein
  • subsequent systemic therapy
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire